Group 1 - The company Yonghe Medical (02279) announced changes to its nomination committee effective from October 28, 2025 [1] - Independent non-executive director Mr. Li Xiaopei will no longer serve as a member of the nomination committee [1] - Independent non-executive director Ms. Liang Jihong has been appointed as a member of the nomination committee [1]

Yonghe Medical Group Co., Ltd. 雍禾醫療集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2279） 董事名單及其角色和職能 雍禾醫療集團有限公司董事會（「董事會」）成員載列如下。 執行董事 張玉先生 張輝先生 韓志梅女士 梁繼紅女士 陳炳鈞先生 李小培先生 1 附註： C 相關董事會委員會主席 M 相關董事會委員會成員 香港 非執行董事 耿嘉琦先生 獨立非執行董事 2025年10月28日 2 董事會下設三個委員會。下表提供各董事會成員所服務的委員會成員資料。 委員會 董事 審核委員會 薪酬委員會 提名委員會 張玉先生 M C 張輝先生 韓志梅女士 耿嘉琦先生 M 梁繼紅女士 M 陳炳鈞先生 C C M 李小培先生 M M ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Yonghe Medical Group Co., Ltd. 雍禾醫療集團有限公司 （於開曼群島註冊成立的有限公司） (ii) 獨立非執行董事梁繼紅女士已獲委任為提名委員會成員。 經上述變動後，提名委員會由三名成員組成，即張玉先生（董事長）、陳炳鈞先生 及梁繼紅女士。 上述委任乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）以及於2025 年7月1日生效的上市規則附錄C1第二部分第B.3.5條所載之企業管治守則之修訂 而作出。董事會相信，實施該等變動將加強董事會的效率及多元化，並進一步提 升本公司之整體企業管治常規。 承董事會命 雍禾醫療集團有限公司 董事長 張玉 （股份代號：2279） 提名委員會組成變動 雍禾醫療集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董 事」）會（「董事會」）謹此宣佈自2025年10月28日起，本公司提名委員會（「提名委 員會」）組成變動如下： ( ...

（股份代號：2279） （「本公司」） 員工多元化政策 （經於2025年10月28日之董事會決議採納並生效） 2. 願景 3. 政策聲明 Yonghe Medical Group Co., Ltd. 雍禾醫療集團有限公司 （於開曼群島註冊成立的有限公司） 3.1. 為達致可持續及均衡的發展，本公司視提升員工的多元化及包容性為支 持其達到戰略目標及其可持續發展的關鍵元素。本公司將多元化及包容 性視為創新及成長的基本動力。 3.2. 本公司在設定員工組成時，會從多個方面考慮多元化，包括但不限於性 別、年齡、婚姻狀況、家庭狀況、種族、民族、宗教、文化及教育背 景、殘疾、性取向、專業經驗、技能、知識、服務任期及本公司提名委 員會（「提名委員會」）可能不時認為相關及適用之任何其他因素。 4. 可計量目標 2 3.3. 所有員工之任命均以用人唯才為原則，並會依循客觀標准考慮候選人， 當中會考慮多元化的裨益及本公司的需要，不會只側重單一的多元化層 面。資歷、經驗、技能、潛力及表現是本公司作出所有僱傭相關決定時 考慮的主要因素。 3.4. 本公司會培養背景更廣更多元化而富工作經驗和技能的僱員，目標假以 時日讓他們升任高級管理 ...

Yonghe Medical Group Co., Ltd. 雍禾醫療集團有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code: 2279) （股份代號：2279） Board Diversity Policy 董事會成員多元化政策 1 Yonghe Medical Group Co., Ltd. 雍禾醫療集團有限公司 (the "Company") （「本公司」） Board Diversity Policy 董事會成員多元化政策 （中文本為翻譯稿，僅供參考用） 本公司明白並深信董事會成員多元化對提 升公司的表現素質的裨益。 政策聲明 1. Purpose This Policy aims to set out the approach to achieve diversity on the Company's board (the "Board") of directors (the "Directors"). 2. Vision The Company recognise ...

Core Viewpoint - Southbound funds have significantly reduced their holdings in Yonghe Medical (02279.HK), indicating a potential shift in investor sentiment towards the company [1][2]. Group 1: Shareholding Changes - On October 21, 2025, southbound funds reduced their holdings by 126,000 shares, representing a decrease of 0.74% [2]. - Over the past five trading days, there has been a cumulative net reduction of 461,000 shares, with reductions occurring on five separate days [1]. - In the last twenty trading days, the total net reduction reached 1,067,000 shares, with reductions on all twenty days [1]. Group 2: Current Holdings - As of now, southbound funds hold 17,006,000 shares of Yonghe Medical, which accounts for 3.22% of the company's total issued ordinary shares [1]. Group 3: Company Overview - Yonghe Medical Group Limited is a holding company specializing in hair-related medical services, offering a comprehensive range of services including hair transplant medical care, medical hair maintenance, routine care, and other supporting services [2]. - The company has established a brand matrix centered around "Yonghe Medical," which includes specialized brands such as "Yonghe Hair Transplant," "Shiyunxun" for medical hair maintenance, "Yonghe Hair Origin" for female aesthetic hair transplant, and "Hafada" for medical wigs [2]. - Yonghe Medical primarily operates in the domestic market of China, providing professional medical hair health management services through its independent Shiyunxun Medical Hair Health Center [2].

Group 1 - The core point of the article highlights the recent reduction in holdings of Yonghe Medical (02279.HK) by southbound funds, with a total net reduction of 139,000 shares over the last 20 trading days [1][2] - As of October 15, 2025, southbound funds hold 17,409,000 shares of Yonghe Medical, representing 3.31% of the company's total issued ordinary shares [1][2] - The company has experienced a consistent trend of share reduction, with southbound funds reducing their holdings for five consecutive days, totaling a decrease of 55,000 shares on October 15, 2025 [1][2] Group 2 - Yonghe Medical Group Limited specializes in providing hair-related medical services, including hair transplant medical services, medical hair care, routine maintenance, and other supporting services [2] - The company has established a comprehensive brand matrix centered around "Yonghe Medical," which includes specialized brands for hair transplant, medical hair care, and aesthetic hair transplant services [2] - Yonghe Medical primarily operates in the domestic market of China, focusing on professional medical hair health management services [2]

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 雍禾醫療集團有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02279 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 525,224,416 | | 248,000 | | 525,472,416 | | 增加 / 減少 (-) | | | | 0 | 0 | | | | 本月底結存 | | | 525,224,416 | | 248,000 | | 525,472,416 | ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Yonghe Medical (02279.HK) by 12,000 shares on September 19, 2025, marking a total net reduction of 257,500 shares over the past five trading days and 1,214,000 shares over the past 20 trading days [1][2] - As of now, southbound funds hold 17,722,000 shares of Yonghe Medical, which accounts for 3.37% of the company's total issued ordinary shares [1][2] Group 2 - Yonghe Medical Group Limited is a holding company specializing in providing hair-related medical services, offering a one-stop solution that includes hair transplant medical services, medical hair care, routine maintenance, and other supporting services [2] - The company has established a brand matrix centered around "Yonghe Medical," which includes professional hair transplant brand "Yonghe Hair Transplant," medical hair care brand "Shiyunxun," female aesthetic hair transplant brand "Yonghe Hair Origin," and medical wig brand "Hafada" [2] - Yonghe Medical operates primarily in the domestic market of China, providing specialized medical hair health management services through its independent Shiyunxun Medical Hair Care Center [2]